<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle">
<p class="DocumentTitle"><strong>KLOR-CON- potassium chloride powder, for solution </strong><br>Cardinal Health<br></p>
<p class="disclaimer">Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. <a href="http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/SelectedEnforcementActionsonUnapprovedDrugs/default.htm">For further information about unapproved drugs, click here.</a></p>
</div>
<h1>KLOR-CON<span class="Sup">® </span><br>Powder (Potassium Chloride for Oral Solution, USP) 20 mEq <br> <br>KLOR-CON<span class="Sup">®</span>/25 <br>Powder (Potassium Chloride for Oral Solution, USP) 25 mEq</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_b47d0c82-639e-4f1e-a581-dd47db1bb4ae"></a><a name="section-1"></a><p></p>
<h1>Description</h1>
<p class="First">Fruit-flavored KLOR-CON<span class="Sup">®</span> and KLOR-CON<span class="Sup">®</span>/25 Powder (Potassium Chloride for Oral Solution, USP) are oral potassium supplements offered as powder for reconstitution in individual packets. Each packet of KLOR-CON<span class="Sup">® </span>powder contains potassium 20 mEq and chloride 20 mEq provided by potassium chloride 1.5 g. Each packet of KLOR-CON<span class="Sup">®</span>/25 powder contains potassium 25 mEq and chloride 25 mEq provided by potassium chloride 1.875 g. KLOR-CON<span class="Sup">®</span> and KLOR-CON<span class="Sup">®</span>/25 are sugar-free. Inactive ingredients: FD&amp;C Yellow No. 6, malic acid, neotame, silicon dioxide, and natural and/or artificial flavors.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_7cce359a-4a95-4543-abd7-8a850b231184"></a><a name="section-2"></a><p></p>
<h1>Clinical Pharmacology</h1>
<p class="First">Potassium ion is the principal intracellular cation of most body tissues. Potassium ions participate in a number of essential physiological processes, including the maintenance of intracellular tonicity, the transmission of nerve impulses, the contraction of cardiac, skeletal, and smooth muscle and the maintenance of normal renal function.</p>
<p>Potassium depletion may occur whenever the rate of potassium loss through renal excretion and/or loss from the gastrointestinal tract exceeds the rate of potassium intake. Such depletion usually develops slowly as a consequence of prolonged therapy with oral diuretics, primary or secondary hyperaldosteronism, <span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">diabetic ketoacidosis</span>, severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, or inadequate replacement of potassium in patients on prolonged parenteral nutrition. Potassium depletion due to these causes is usually accompanied by a concomitant deficiency of chloride and is manifested by <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> and <span class="product-label-link" type="condition" conceptid="4030381" conceptname="Metabolic alkalosis">metabolic alkalosis</span>. Potassium depletion may produce <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, disturbances of cardiac rhythm (primarily ectopic beats), prominent U-waves in the electro-cardiogram, and in advanced cases <span class="product-label-link" type="condition" conceptid="4193951" conceptname="Flaccid paralysis">flaccid paralysis</span> and/or impaired ability to concentrate urine. </p>
<p>Potassium depletion associated with <span class="product-label-link" type="condition" conceptid="4030381" conceptname="Metabolic alkalosis">metabolic alkalosis</span> is managed by correcting the fundamental causes of the deficiency whenever possible and administering supplemental potassium chloride, in the form of high potassium food or potassium chloride solution or tablets.</p>
<p>In rare circumstances (e.g., patients with <span class="product-label-link" type="condition" conceptid="4070448" conceptname="Renal tubular acidosis">renal tubular acidosis</span>) potassium depletion may be associated with <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span> and <span class="product-label-link" type="condition" conceptid="4253927" conceptname="Hyperchloremia">hyperchloremia</span>. In such patients potassium replacement should be accomplished with potassium salts other than the chloride, such as potassium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span>, potassium citrate or potassium acetate.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_904fd97f-38e3-4809-ad0d-b73162828b3a"></a><a name="section-3"></a><p></p>
<h1>Indications and Usage</h1>
<p class="First">1) For therapeutic use in patients with <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> with or without <span class="product-label-link" type="condition" conceptid="4030381" conceptname="Metabolic alkalosis">metabolic alkalosis</span>; in <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digitalis intoxication</span> and in patients with hypokalemic <span class="product-label-link" type="condition" conceptid="73184" conceptname="Familial periodic paralysis">familial periodic paralysis</span>.</p>
<p>2) For prevention of potassium depletion when the dietary intake of potassium is inadequate in the following conditions: patients receiving digitalis and diuretics for <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>; <span class="product-label-link" type="condition" conceptid="4064161" conceptname="Cirrhosis of liver">hepatic cirrhosis</span> with <span class="product-label-link" type="condition" conceptid="200528" conceptname="Ascites">ascites</span>; states of aldosterone excess with normal renal function; potassium-losing <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">nephropathy</span> and certain diarrheal states.</p>
<p>3) The use of potassium salts in patients receiving diuretics for uncomplicated <span class="product-label-link" type="condition" conceptid="320128" conceptname="Essential hypertension">essential hypertension</span> is often unnecessary when such patients have a normal dietary pattern. Serum potassium should be checked periodically, however, and if <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> occurs, dietary supplementation with potassium-containing foods may be adequate to control milder cases. In more severe cases supplementation with potassium salts may be indicated.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_f5c08577-3bc2-42a5-ac44-c14fcd0669d2"></a><a name="section-4"></a><p></p>
<h1>Contraindications</h1>
<p class="First">Potassium supplements are contraindicated in patients with <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> since a further increase in serum potassium concentration in such patients can produce <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>. <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span> may complicate any of the following conditions: <span class="product-label-link" type="condition" conceptid="198185" conceptname="Chronic renal failure">chronic renal failure</span>, systemic <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span> such as <span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">diabetic acidosis</span>, acute <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, extensive tissue breakdown as in severe <span class="product-label-link" type="condition" conceptid="4022094" conceptname="Thermal burn">burns</span>, <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">adrenal insufficiency</span>, or the administration of a potassium-sparing diuretic (e.g., spironolactone, triamterene or amiloride). Contraindicated in persons demonstrating <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> to any of the components of the powder.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_c796375f-66eb-4c28-9c48-c3964ac1ed97"></a><a name="section-5"></a><p></p>
<h1>Warnings</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d4d1979e-744e-4730-b88c-9b3337574471"></a><a name="section-5.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span></h2>
<p class="First">In patients with impaired mechanisms for excreting potassium, the administration of potassium salts can produce <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> and <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>. This occurs most commonly in patients given potassium by the intravenous route but may also occur in patients given potassium orally. Potentially fatal <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> can develop rapidly and be asymptomatic. </p>
<p>The use of potassium salts in patients with chronic <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>, or any other condition which impairs potassium excretion, requires particularly careful monitoring of the serum potassium concentration and appropriate dosage adjustments.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_062ccf9b-2525-49a4-afef-778deb5835b9"></a><a name="section-5.2"></a><p></p>
<h2>Interaction with Potassium-Sparing Diuretics</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> should not be treated by the concomitant administration of potassium salts and a potassium-sparing diuretic (e.g., spironolactone, triamterene or amiloride), since the simultaneous administration of these agents can produce severe <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c0e103bc-2924-4f8a-9afc-dfbc41e53e25"></a><a name="section-5.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">Metabolic Acidosis</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> in patients with <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span> should be treated with an alkalinizing potassium salt such as potassium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span>, potassium citrate or potassium acetate.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_63c77fac-4fb7-4971-a165-a50e47d6e6b3"></a><a name="section-6"></a><p></p>
<h1>Precautions</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_06b43134-633c-4bee-9572-0f1bd85ee9d1"></a><a name="section-6.1"></a><p></p>
<h2>General</h2>
<p class="First">The diagnosis of potassium depletion is ordinarily made by demonstrating <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> in a patient with a clinical history suggesting some cause for potassium depletion.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="i4i_lab_tests_id_4a7056b8-ccaf-40b7-bb69-f7b852b018e2"></a><a name="section-6.2"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">In interpreting the serum potassium level, the physician should be aware that acute <span class="product-label-link" type="condition" conceptid="438730" conceptname="Alkalosis">alkalosis</span> <span class="Italics">per se</span> can produce <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> in the absence of a deficit in total body potassium while <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acute acidosis</span> <span class="Italics">per se</span> can increase the serum potassium concentration into the normal range even in the presence of a reduced total body potassium. The treatment of potassium depletion, particularly in the presence of cardiac disease, <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>, or <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span>, requires careful attention to acid-base balance and appropriate monitoring of serum electrolytes, the electrocardiogram, and the clinical status of the patient.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_e657dcaa-8d2d-4219-a84b-f72c52e8e4b7"></a><a name="section-6.3"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Carcinogenicity, mutagenicity and fertility studies in animals have not been performed. Potassium is a normal dietary constituent.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_2a14e56b-1a67-4d35-9778-a407494ce818"></a><a name="section-6.4"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="i4i_teratogenic_id_098d228a-7865-4433-b92c-c39f4be20781"></a><a name="section-6.4.1"></a><p></p>
<h3>Pregnancy Category C</h3>
<p class="First">Animal reproduction studies have not been conducted with potassium chloride. It is not known if potassium chloride causes fetal harm when administered to a pregnant woman or affects reproductive capacity. Potassium chloride should be given to a pregnant woman only if clearly needed.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_aa6be4a0-7c9f-4f9c-8913-c59ca3712272"></a><a name="section-6.5"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from oral potassium supplements, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_9be47412-73aa-404c-8ee0-b372a43327df"></a><a name="section-6.6"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness in children have not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_cb72393f-eef2-40da-95e0-0b8c8651fd55"></a><a name="section-7"></a><p></p>
<h1>Adverse Reactions</h1>
<p class="First">The most common adverse reactions to oral potassium salts are <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal discomfort</span>, and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. These symptoms are due to irritation of the gastrointestinal tract and are best managed by diluting the preparation further, taking the dose with meals, or reducing the dose.</p>
<p>One of the most severe adverse effects is <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> (see <span class="Bold"><a href="#i4i_contraindications_id_f5c08577-3bc2-42a5-ac44-c14fcd0669d2">Contraindications</a>, <a href="#i4i_warnings_id_c796375f-66eb-4c28-9c48-c3964ac1ed97">Warnings </a></span>and<span class="Bold"><a href="#i4i_overdosage_id_253feb54-5412-4063-94ec-63024bc3f9d2"> Overdosage</a>). </span><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Skin rash</span> has been reported rarely.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_253feb54-5412-4063-94ec-63024bc3f9d2"></a><a name="section-8"></a><p></p>
<h1>Overdosage</h1>
<p class="First">The administration of oral potassium salts to persons with normal excretory mechanisms for potassium rarely causes serious <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>. However, if excretory mechanisms are impaired or if potassium is administered too rapidly intravenously, potentially fatal <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> can result (see <span class="Bold"><a href="#i4i_contraindications_id_f5c08577-3bc2-42a5-ac44-c14fcd0669d2">Contraindications </a></span>and <span class="Bold"><a href="#i4i_warnings_id_c796375f-66eb-4c28-9c48-c3964ac1ed97">Warnings</a>). </span>It is important to recognize that <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> is usually asymptomatic and may be manifested only by an increased serum potassium concentration and characteristic electrocardiographic changes (peaking of T-waves, loss of P-wave, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> of S-T segment and prolongation of the QT interval). Late manifestations include muscle <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span> and <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">cardiovascular collapse</span> from <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>.</p>
<p>Treatment measures for <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> include the following: (1) elimination of foods and medications containing potassium and of potassium-sparing diuretics; (2) intravenous administration of 300 to 500 mL/hr of 10% dextrose solution containing 10-20 units of insulin per 1000 mL; (3) correction of <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span>, if present, with intravenous sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span>; (4) use of exchange resins, hemodialysis or peritoneal dialysis.</p>
<p>In treating <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>, it should be recalled that in patients who have been stabilized on digitalis, too rapid a lowering of the serum potassium concentration can produce <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digitalis toxicity</span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_b6f78406-9ad5-4d99-aad4-ea34b0136db5"></a><a name="section-9"></a><p></p>
<h1>Dosage and Administration</h1>
<p class="First">Dosage must be adjusted to the individual needs of each patient but is typically in the range of 20 mEq per day for the prevention of <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> to 40-100 mEq per day or more for the treatment of potassium depletion.</p>
<p>The usual adult dose is 20-100 mEq of potassium per day (one KLOR-CON<span class="Sup">®</span> 20 mEq packet 1 to 5 times daily after meals or one KLOR-CON<span class="Sup">® </span>/25 25 mEq packet 1 to 4 times daily after meals).</p>
<p>The contents of each KLOR-CON<span class="Sup">®</span> packet should be dissolved in at least 4 ounces of <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> water or other beverage. The contents of each KLOR-CON<span class="Sup">® </span>/25 packet should be dissolved in at least 5 ounces of <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> water or other beverage. These preparations, like other potassium supplements, must be properly diluted to avoid the possibility of <span class="product-label-link" type="condition" conceptid="4318531" conceptname="Gastrointestinal irritation">gastrointestinal irritation</span>.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_32cbd50b-cc3b-410e-896b-bf5c7322920c"></a><a name="section-10"></a><p></p>
<h1>How Supplied</h1>
<p class="First">KLOR-CON<span class="Sup">® </span>Powder (Potassium Chloride for Oral Solution, USP) 20 mEq is supplied in cartons of 30 packets (NDC 0245-0035-30) and cartons of 100 packets (NDC 0245-0035-01). Each packet contains potassium 20 mEq and chloride 20 mEq provided by potassium chloride 1.5 g.</p>
<p>KLOR-CON<span class="Sup">® </span>/25 Powder (Potassium Chloride for Oral Solution, USP) 25 mEq is supplied in cartons of 30 packets (NDC 0245-0037-30) and cartons of 100 (NDC 0245-0037-01). Each packet contains potassium 25 mEq and chloride 25 mEq provided by potassium chloride 1.875g. </p>
<div class="Section" data-sectionCode="44425-7">
<a name="i4i_storage_id_b905ff69-3a65-46d7-97f2-ac8123df1ad6"></a><a name="section-10.1"></a><p></p>
<p class="First">Store at controlled room temperature, 15-30°C (59-86°F).</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_eb23d525-d7c7-4dc4-8e18-c8d35e922812"></a><a name="section-11"></a><p></p>
<p class="First">©1999 Upsher-Smith Laboratories, Inc. All Rights Reserved.</p>
<p>Revised 0809<br>103683-01</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_73441475-a928-4348-a25a-8b6b5e5dc625"></a><a name="section-12"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<p class="First">Klor-Con<span class="Sup">®</span> 20 mEq POWDER</p>
<p>Potassium Chloride for Oral Solution, USP</p>
<p>10 Packets</p>
<div class="Figure"><img alt="bag label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bae3548f-40fe-4ef5-adb3-eb4cef6f735d&amp;name=371ef590-b063-43ae-9532-135194cf13dc-01.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>KLOR-CON 		
					</strong><br><span class="contentTableReg">potassium chloride powder, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:55154-5605(NDC:0245-0035)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Potassium Chloride</strong> (Potassium Cation) </td>
<td class="formItem">Potassium Cation</td>
<td class="formItem">20 meq</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Neotame</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Malic Acid</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C YELLOW NO. 6</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">ORANGE</td>
<td class="formLabel">Score</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">ORANGE</td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:55154-5605-0</td>
<td class="formItem">10  in 1 BAG</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Unapproved drug other</td>
<td class="formItem"></td>
<td class="formItem">11/01/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Cardinal Health
							(188557102)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Cardinal Health</td>
<td class="formItem"></td>
<td class="formItem">188557102</td>
<td class="formItem">REPACK(55154-5605)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 8/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>371ef590-b063-43ae-9532-135194cf13dc</div>
<div>Set id: bae3548f-40fe-4ef5-adb3-eb4cef6f735d</div>
<div>Version: 2</div>
<div>Effective Time: 20120801</div>
</div>
</div> <div class="DistributorName">Cardinal Health</div></p>
</body></html>
